ClinicalTrials.gg
Not yet recruitingNCT06885645Updated Apr 3, 2025

First-In-Human Study in Participants With Advanced Solid Tumors

A Phase 1 interventional study of KH815 for injection in Advanced Solid Tumors, sponsored by Chengdu Kanghong Biotech Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Chengdu Kanghong Biotech Co., Ltd. (part of Chengdu Kanghong Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Read the detailed description

The study will use BOIN design for dosing cohort management to determine the MTD and RDE/RP2D. The starting dose of KH815 is 0.5 mg/kg, followed by 1.0 to 4.0 mg/kg. The investigational product will be administered on Day 1 every 3 weeks via intravenous infusion, and the first cycle of KH815 treatment is for DLT evaluation. Enrolled patients will be sequentially assigned to the planned dose levels as required by the protocol and treated with KH815 IV Q3W to observe the occurrence of treatment related AEs and dose limiting toxicities. The dose-escalation decision will be determined per discussion between Safety Review Committee and Sponsor if deemed necessary. Moreover, the SRC is also responsible for deciding the MTD and the recommended dose level for dose-expansion study.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Chengdu Kanghong Biotech Co., Ltd. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed, written IRB-approved .
  2. Male or female.
  3. Aged 18 \~ 75 years.
  4. of at least 3 months.
  5. or cytologically confirmed advanced or unresectable solid tumors for wihch failure or difficult to be treated with standard therapies, or not suitable for standard therapies.
  6. by CT/MRI as defined in v1.1.
  7. (ECOG) Performance Status 0 or 1.

Exclusion criteria

exclusion criteria:

  1. Pregnant or lactating women.
  2. Received cancer-directed therapy within the following timeframes:

    • Major surgery within 4 weeks or will be expected to require major surgical treatment during the study period.
    • Radical radiotherapy or chest palliative radiotherapy within 4 weeks, or palliative radiotherapy at any other sites except chest within 2 weeks.
    • Antibody-based anti-cancer therapies, macromolecular protein products or cytotherapies within 4 weeks.
    • Hormonal anti-tumor therapy within 2 weeks.
    • Chemotherapy (including non-antibody based immunotherapy therapy) within 2 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 times half life of the chemotherapeutic agent (whichever is longer).
    • Any natural medicine with anti-tumor effect within 2 weeks.
    • Tyrosine kinase inhibitor (TKI) treatment within 1 week.
  3. Received experimental drug therapy or participated in a clinical study of a medical device within 4 weeks prior to first infusion of KH815.
  4. Known history of unstable angina, myocardial infarction (MI), or congestive heart failure (CHF) ( Class II-IV) within 6 months or arrhythmia (other than stable atrial fibrillation or paroxysmal superventricular tachycardia) requiring anti-arrhythmia therapy
  5. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) and/or diabetes ( ≥ 9.0%).
  6. Uncontrolled pleural effusion or pericardial effusion. Ascites requiring repeated drainage surgery (once a month or more frequently).
  7. Patients with moderate to severe respiratory dyspnea due to severe primary lung disease or complications of advanced [rated as grade 3/4 by modified Medical Research Council (mMRC) scale] (see Appendix 3), or requiring continuous oxygen therapy, or acute exacerbations of (AECOPD), or history of interstitial lung disease (ILD)/pneumonia, or ILD/ pneumonia that could not be ruled out on imaging during screening, or any disease/connective tissue disease (e.g. Rheumatoid arthritis, Sjogren's syndrome, sarcoidosis) with lungs involvement.
  8. Grade ≥2 anorexia, nausea, vomiting, or diarrhea within 2 weeks prior to first infusion of KH815.
  9. Active central nervous system (CNS) (defined as untreated and has symptoms such as consciousness disorder, or need or anticonvulsant therapy to control symptoms) within 1 month prior to first infusion of KH815.
  10. History of significant active bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months prior to first infusion of KH815.
  11. Newly diagnosed thromboembolic events requiring treatment within 6 months prior to first infusion of KH815 [patients with controlled and stable lower extremity deep venous thrombosis (DVT) or catheter related thrombosis (CRT) could be included].
  12. Known history of other malignancies diagnosed within 5 years prior to first infusion of KH815 (patients with basal cell carcinoma, skin squamous cell carcinoma and carcinoma in situ, and with radical resection for more than 3 years could be enrolled).
  13. Known history of severe dry eye, severe meibomian gland disease or blepharitis, incurable or delayed corneal healing resulted from the keratopathy or macular disease.
  14. Known to be allergic to any component of KH815, or known history of grade ≥3 anaphylaxis to macromolecular protein products/antibody-based therapy, or known history of grade ≥3 drug-related AEs with the use of topoisomerase I inhibitors such as irinotecan.
  15. Patients who require use of strong inhibitors or inducers of at least 14 days prior to the first infusion of KH815 and throughout study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this study.
  16. (HIV) antibody positive. Has an active or uncontrolled (HBV) and/or (HCV) infection. Patients with untreated or ongoing tuberculosis, but those who have undergone standard anti-tuberculosis treatment and have been confirmed as cured by the investigator could be included.
  17. Known history of allogeneic cell or solid organ transplantation.
  18. Active infection requiring systemic treatment within 2 weeks prior to the first infusion of KH815.
  19. Live or within 28 days prior to KH815 administration and live or live attenuated vaccine planned over the course of the study.
  20. Known history of psychotropic substance abuse, alcohol abuse, or drug abuse.
  21. Psychological, social, familial, or geographical factors that would prevent regular follow-up. Adults under guardianship, curatorship, safeguard of justice, or family empowerment measure are not eligible.
  22. Otherwise considered inappropriate for the study by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    KH815 for Injection

    Phase I: Dose Escalation Phase I part of the study:dose1-dose5 of KH815 for injection

    Drug: KH815 for injection

Interventions

  • DrugKH815 for injection

    KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    To determine the maximum tolerated dose (MTD)

    Time frame: Postdose of last participant up to 12 months

  2. Dose Limiting Toxicities (DLTs)

    To determine the Dose Limiting Toxicities (DLTs).

    Time frame: Baseline up to 21 days after the first dose

  3. Recommended Doses for Expansion (RDEs)

    To determine the recommended doses for expansion (RDEs).

    Time frame: Postdose of last participant up to 12 months

Secondary outcomes

  1. Cmax

    To characterize the Cmax of KH815-ADC, KH815 TAB, free Drug-E payload and free Drug-T payload.

    Time frame: Post last dose up to Day 60

  2. Tmax

    To characterize the Tmax of KH815-ADC, KH815 TAB, free Drug-E payload and free Drug-T payload.

    Time frame: Post last dose up to Day 60

  3. AUC0-t

    To characterize the AUC0-t of KH815-ADC, KH815 TAB, free Drug-E payload and free Drug-T payload.

    Time frame: Post last dose up to Day 60

  4. AUCtau

    To characterize the AUCtau of KH815-ADC, KH815 TAB, free Drug-E payload and free Drug-T payload.

    Time frame: Post last dose up to Day 60

  5. t1/2

    To characterize the t1/2 of KH815-ADC, KH815 TAB, free Drug-E payload and free Drug-T payload.

    Time frame: Post last dose up to Day 60

  6. Objective Response Rate (ORR)

    To evaluate the objective response rate (ORR) of KH815 for injection when administered intravenously (IV) as monotherapy at the RDEs to patients with advanced solid tumors.

    Time frame: Postdose of last participant up to 12 months

  7. Phase I: ADA prevalence and incidence

    To assess the prevalence and incidence of anti-drug antibody (ADA) of KH815

    Time frame: Post last dose up to Day 60

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Jun 2027, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 20, 2025
StartEst.
Apr 30, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06885645
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Apr 30, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 3, 2025

Study contacts

Fei Ma, Dr.
Contact
drmafei@126.com
+86 10 87788114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion